Skip to main content

Table 1 Mean ± SD, median (IQR), or proportion of the main anthropometric, clinical, functional and radiological variables in the three groups of participants

From: Characterisation of COPD heterogeneity in the ECLIPSE cohort

  COPD
(n = 2164)
Smoking controls
(n = 337)
Non-smoking controls
(n = 245)
p value
Clinical data
Age (years) 63.4 ± 7.1a, b 55.4 ± 9.0 54.1 ± 9.0 < 0.001
Pack-years 48.6 ± 27.1 a, b 31.6 ± 21.5b 0.2 ± 1.1 < 0.001
Current Smokers (%) 36a 61   < 0.001
BMI (kg/m2) 26.5 ± 5.7b 26.8 ± 4.6 27.7 ± 5.4 0.004
FFMI (kg/m2) 17.2 ± 2.8 17.1 ± 2.6 17.2 ± 2.7 0.842
mMRC Score 1.7 ± 1.1 a, b 0.2 ± 0.5b 0.1 ± 0.3 < 0.001
SGRQ-C total score 50.1 ± 20.3 a, b 9.6 ± 12.3b 4.8 ± 6.5 < 0.001
Number of exacerbationsc 0.9 ± 1.2 a, b 0.0 ± 0.1 0.0 ± 0.1 < 0.001
Heart trouble (%) 26 a, b 11 9 < 0.001
Heart attack (%) 9 a, b 3 1 < 0.001
Stroke (%) 4d 2 1 0.018
Heart failure (%) 7 a, b 1 0 < 0.001
Arrhythmia (%) 12a, d 5 7 < 0.001
Osteoporosis (%) 14 a, b 5 5 < 0.001
Diabetes (%) 10b 7 5 0.003
Inflammatory bowel disease (%) 5e 2 4 0.127
Peptic ulcer (%) 11b 7d 3 < 0.001
Reflux/heartburn (%) 27d 29d 19 0.031
Depression requiring tx (%) 17 15 14 0.506
Physiology
FEV1 (% predicted) 48.3 ± 15.8 a, b 108.6 ± 12.0d 114.8 ± 13.9 < 0.001
FEV1/FVC (%) 44.8 ± 11.6 a, b 79.2 ± 5.2d 81.1 ± 5.2 < 0.001
FEV1 reversibility (%) 10.7 ± 13.7 a, b 4.5 ± 5.8d 2.7 ± 4.5 < 0.001
Distance walked (metres) 369 ± 122    
BODE index 3.2 ± 2.1    
Imaging
Emphysema (%) 17.6 ± 12.2 a, b 2.4 ± 3.1b 4.1 ± 4.2 < 0.001
  1. ap < 0.01 vs. smoking controls; b< 0.01 vs. non-smoking controls; c In the year prior to study dp < 0.05 vs. non-smoking controls. entry. ep < 0.05 vs. smoking controls. Abbreviations: tx: treatment.